<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00757679</url>
  </required_header>
  <id_info>
    <org_study_id>F02207 GE 205</org_study_id>
    <nct_id>NCT00757679</nct_id>
  </id_info>
  <brief_title>Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran</brief_title>
  <official_title>Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran. An Exploratory Placebo-controlled Clinical Trial in Fibromyalgia Out-patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <brief_summary>
    <textblock>
      Evaluation of the antinociceptive effect of 7 weeks of treatment with milnacipran, compared&#xD;
      to placebo, in fibromyalgia out-patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the antinociceptive effect of 7 weeks of treatment with milnacipran, compared to placebo, in fibromyalgia outpatients.</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The analgesic effect of 7 weeks of treatment with milnacipran, compared to placebo</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation of the antinociceptive and analgesic effects of milnacipran with the cytochrome CYP2D6 and COMT phenotype polymorphism determinations</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The safety/tolerability and compliance of 8 weeks of treatment with milnacipran</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The therapeutic drug monitoring (TDM) and carry out the PK/PD correlations</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Fibromyalgia Syndrome</condition>
  <arm_group>
    <arm_group_label>Milnacipran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milnacipran</intervention_name>
    <description>capsules</description>
    <arm_group_label>Milnacipran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with FMS according to the 1990 ACR criteria&#xD;
&#xD;
          -  patient willing to withdraw from CNS-active therapies commonly used for FMS, including&#xD;
             anti-depressants, anti-convulsivants, opiates&#xD;
&#xD;
          -  patient willing to discontinue treatment with tender and trigger point injections,&#xD;
             joint injections and anesthetics&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe psychiatric illness&#xD;
&#xD;
          -  current Major Depressive Episode (MDE)&#xD;
&#xD;
          -  significant risk of suicide&#xD;
&#xD;
          -  history of substance abuse&#xD;
&#xD;
          -  epilepsy&#xD;
&#xD;
          -  myocardial infarction in the past 24 months&#xD;
&#xD;
          -  active cardiac disease&#xD;
&#xD;
          -  congestive heart failure&#xD;
&#xD;
          -  prosthetic heart valve&#xD;
&#xD;
          -  haemodynamically significant valvular heart disease&#xD;
&#xD;
          -  known cardiac rhythm anomalies or conduction abnormalities&#xD;
&#xD;
          -  unstable and uncontrolled arterial hypertension or supine arterial blood pressure over&#xD;
             160/90 mmHg&#xD;
&#xD;
          -  pulmonary dysfunction&#xD;
&#xD;
          -  active liver disease&#xD;
&#xD;
          -  renal impairment&#xD;
&#xD;
          -  documented autoimmune disease&#xD;
&#xD;
          -  current systemic infection&#xD;
&#xD;
          -  active cancer, except basal cell carcinoma or current cancer therapy&#xD;
&#xD;
          -  severe sleep apnoea&#xD;
&#xD;
          -  active peptic ulcer or inflammatory bowel disease (except IBS)&#xD;
&#xD;
          -  unstable endocrine disease&#xD;
&#xD;
          -  pregnancy or breastfeeding&#xD;
&#xD;
          -  concomitant use of non selective MAO inhibitors, MAO-A or -B inhibitors, tricyclics,&#xD;
             tetracyclics, SSRIs, NARIs, SNRIs, epinephrine, norepinephrine, clonidine and related&#xD;
             compounds, long-acting benzodiazepines&#xD;
&#xD;
          -  concomitant use of oral anticoagulants, anticonvulsants, type Ic antiarrythmics,&#xD;
             lithium&#xD;
&#xD;
          -  concomitant use of hypericum and SAMe&#xD;
&#xD;
          -  concomitant use of digitalis preparations&#xD;
&#xD;
          -  regular use of centrally-acting muscle relaxants&#xD;
&#xD;
          -  concomitant use of strong analgesics, including tramadol, codeine or opiates&#xD;
&#xD;
          -  any factor known to affect the HPA axis or autonomic function such as cigarette&#xD;
             smoking (regularly over 25 cigarettes a day)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jules Desmeules, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier HUG Gen√®ve - SUISSE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology &amp; Toxicology Multidisciplinary Pain Centre</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>September 22, 2008</study_first_submitted>
  <study_first_submitted_qc>September 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2008</study_first_posted>
  <last_update_submitted>July 10, 2013</last_update_submitted>
  <last_update_submitted_qc>July 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milnacipran</mesh_term>
    <mesh_term>Levomilnacipran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

